These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 1722775)

  • 1. Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma.
    Fukuda H; Seya T; Hara T; Matsumoto M; Kinoshita T; Masaoka T
    Immunol Lett; 1991 Aug; 29(3):205-9. PubMed ID: 1722775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of complement regulatory proteins, CD35 (CR1), CD46 (MCP) and CD55 (DAF) in human haematological malignancies.
    Hara T; Kojima A; Fukuda H; Masaoka T; Fukumori Y; Matsumoto M; Seya T
    Br J Haematol; 1992 Oct; 82(2):368-73. PubMed ID: 1384649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
    Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
    Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of complement regulatory proteins CR1, DAF, MCP and CD59 in haematological malignancies.
    Guc D; Canpinar H; Kucukaksu C; Kansu E
    Eur J Haematol; 2000 Jan; 64(1):3-9. PubMed ID: 10680700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative complement pathway-mediated myeloid cell cytotoxicity: repertoire of membrane factors participating in regulation of C3 deposition and cytolysis.
    Matsumoto M; Sugita Y; Seya T
    Eur J Immunol; 1991 Aug; 21(8):1787-92. PubMed ID: 1714391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage.
    Lublin DM; Coyne KE
    J Exp Med; 1991 Jul; 174(1):35-44. PubMed ID: 1711565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria.
    Kinoshita T; Medof ME; Silber R; Nussenzweig V
    J Exp Med; 1985 Jul; 162(1):75-92. PubMed ID: 2409211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Paroxysmal nocturnal hemoglobinuria (PNH) deficiency of major complement-regulatory membrane proteins on erythrocytes].
    Ninomiya H; Kobayashi T; Abe T
    Rinsho Ketsueki; 1991 Jun; 32(6):612-7. PubMed ID: 1716325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution of C3-step regulatory proteins of the complement system, CD35 (CR1), CD46 (MCP), and CD55 (DAF), in hematological malignancies.
    Seya T; Matsumoto M; Hara T; Hatanaka M; Masaoka T; Akedo H
    Leuk Lymphoma; 1994 Feb; 12(5-6):395-400. PubMed ID: 7514063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement-mediated tumor cell damage induced by antibodies against membrane cofactor protein (MCP, CD46).
    Seya T; Hara T; Matsumoto M; Sugita Y; Akedo H
    J Exp Med; 1990 Dec; 172(6):1673-80. PubMed ID: 2258699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogenous expression of decay accelerating factor and CD59/membrane attack complex inhibition factor on paroxysmal nocturnal haemoglobinuria (PNH) erythrocytes.
    Shichishima T; Terasawa T; Hashimoto C; Ohto H; Uchida T; Maruyama Y
    Br J Haematol; 1991 Aug; 78(4):545-50. PubMed ID: 1716957
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of the complement regulatory proteins CD21, CD55 and CD59 on Burkitt lymphoma lines: their role in sensitivity to human serum-mediated lysis.
    Kuraya M; Yefenof E; Klein G; Klein E
    Eur J Immunol; 1992 Jul; 22(7):1871-6. PubMed ID: 1378022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of complement regulatory molecules in lung cancer: disappearance of the D17 epitope of CD55 in small-cell carcinoma.
    Sakuma T; Kodama K; Hara T; Eshita Y; Shibata N; Matsumoto M; Seya T; Mori Y
    Jpn J Cancer Res; 1993 Jul; 84(7):753-9. PubMed ID: 7690355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization of the complement regulatory proteins in the normal human kidney.
    Ichida S; Yuzawa Y; Okada H; Yoshioka K; Matsuo S
    Kidney Int; 1994 Jul; 46(1):89-96. PubMed ID: 7523758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of lymphocyte-mediated K562 cytotoxicity by antibodies against complement membrane cofactor protein (CD46) and decay-accelerating factor (CD55).
    Seya T; Kojima A; Hara T; Hazeki K; Sugita Y; Akedo H
    Immunobiology; 1991 Sep; 183(1-2):115-24. PubMed ID: 1718846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor).
    Merry AH; Rawlinson VI; Uchikawa M; Daha MR; Sim RB
    Br J Haematol; 1989 Oct; 73(2):248-53. PubMed ID: 2479410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deficiency of glycosyl-phosphatidylinositol anchored proteins on paroxysmal nocturnal haemoglobinuria (PNH) neutrophils and monocytes: heterogeneous deficiency of decay-accelerating factor (DAF) and CD16 on PNH neutrophils.
    Kawakami Z; Ninomiya H; Tomiyama J; Abe T
    Br J Haematol; 1990 Apr; 74(4):508-13. PubMed ID: 1693286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.
    Kim YU; Kinoshita T; Molina H; Hourcade D; Seya T; Wagner LM; Holers VM
    J Exp Med; 1995 Jan; 181(1):151-9. PubMed ID: 7528766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of a hybrid complement regulatory protein, membrane cofactor protein decay accelerating factor on Chinese hamster ovary. Comparison of its regulatory effect with those of decay accelerating factor and membrane cofactor protein.
    Iwata K; Seya T; Ariga H; Nagasawa S
    J Immunol; 1994 Apr; 152(7):3436-44. PubMed ID: 7511647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloblastic leukemia in paroxysmal nocturnal hemoglobinuria. Evidence of evolution from the abnormal paroxysmal nocturnal hemoglobinuria clone.
    Devine DV; Gluck WL; Rosse WF; Weinberg JB
    J Clin Invest; 1987 Jan; 79(1):314-7. PubMed ID: 2432090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.